CB-011 cells were protected from natural killer (NK) cell-mediated cytotoxicity in vitro and in vivo due to endogenous promoter-driven expression of B2M-HLA-E. Potent antitumor efficacy, when combined with an immune-cloaking armoring strategy to dampen allograft rejection, offers optimized therapeutic potential in multiple myeloma.
10 months ago
Preclinical • Journal • CAR T-Cell Therapy • IO biomarker
|
B2M (Beta-2-microglobulin) • HLA-E (Major Histocompatibility Complex, Class I, E)
These studies support the safety and efficacy profiles of CB-011 for an upcoming first-in-human phase 1 clinical trial evaluating these allogeneic BCMA-specific CAR-T cells in patients with r/r MM.
2 years ago
CAR T-Cell Therapy • IO biomarker • Immune cell
|
CD19 (CD19 Molecule) • B2M (Beta-2-microglobulin) • HLA-E (Major Histocompatibility Complex, Class I, E)